CLOVER BIOPHARMACEUTICALS, LTD. Financials Clover Biopharmaceuticals, Ltd.
Equities
2197
KYG2280A1076
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.345 HKD | -.--% |
|
+4.55% | -44.35% |
| Apr. 12 | Clover Biopharmaceuticals, Ltd. announced that it has received $0.320713 million in funding | CI |
| Apr. 08 | Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 |
|---|---|---|
| Capitalization 1 | 12,815 | 2,957 |
| Enterprise Value (EV) 1 | 10,023 | 1,687 |
| P/E ratio | -2.13 x | -1.03 x |
| Yield | - | - |
| Capitalization / Revenue | - | - |
| EV / Revenue | - | - |
| EV / EBITDA | -4.5 x | -0.72 x |
| EV / FCF | -8,219,769 x | -1,079,723 x |
| FCF Yield | -0% | -0% |
| Price to Book | 10.5 x | -4.43 x |
| Nbr of stocks (in thousands) | 1,158,115 | 1,292,635 |
| Reference price 2 | 11.07 | 2.287 |
| Announcement Date | 4/19/22 | 4/20/23 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Net sales | - | - | - | - |
| EBITDA 1 | -61.76 | -303.1 | -2,226 | -2,337 |
| EBIT 1 | -62.83 | -304.6 | -2,239 | -2,366 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | -48.58 | -912.9 | -6,016 | -2,452 |
| Net income 1 | -48.58 | -912.9 | -6,016 | -2,452 |
| Net margin | - | - | - | - |
| EPS 2 | -0.0641 | -1.205 | -5.195 | -2.225 |
| Free Cash Flow | - | -518.4 | -1,219 | -1,562 |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 10/25/21 | 10/25/21 | 4/19/22 | 4/20/23 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 0.257 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -758.7 | -1,065 | -1,081 | -795 | -517.5 |
| Operating Margin | - | - | - | - | -201,372.37% |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| EPS | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | - | 3/29/22 | 8/23/22 | 3/28/23 | 8/22/23 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Net Debt 1 | 52.5 | 363 | - | - |
| Net Cash position 1 | - | - | 2,791 | 1,270 |
| Leverage (Debt/EBITDA) | -0.85 x | -1.198 x | - | - |
| Free Cash Flow | - | -518 | -1,219 | -1,562 |
| ROE (net income / shareholders' equity) | - | 174% | -5,090% | -890% |
| ROA (Net income/ Total Assets) | - | -27.7% | -42.8% | -29.5% |
| Assets 1 | - | 3,293 | 14,046 | 8,324 |
| Book Value Per Share 2 | -0.0900 | - | 1.050 | -0.5200 |
| Cash Flow per Share 2 | 0.2000 | - | 2.390 | 1.240 |
| Capex 1 | 6.82 | 114 | 59.3 | 77 |
| Capex / Sales | - | - | - | - |
| Announcement Date | 10/25/21 | 10/25/21 | 4/19/22 | 4/20/23 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -44.35% | 57.21M | |
| -1.17% | 102B | |
| +2.87% | 96.09B | |
| +2.13% | 22.28B | |
| -14.77% | 21.4B | |
| -8.79% | 18.14B | |
| -39.98% | 17.02B | |
| -13.21% | 16.09B | |
| +8.55% | 13.83B | |
| +35.75% | 11.97B |
- Stock Market
- Equities
- 2197 Stock
- Financials Clover Biopharmaceuticals, Ltd.
